Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
Rev. Soc. Bras. Med. Trop
;
52: e20180211, 2019. tab, graf
Artículo
en Inglés
| LILACS
| ID: biblio-1003136
ABSTRACT
Abstract Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine antimoniate administration has fewer adverse effects and can be as effective and safe. We describe 12 patients treated with intralesional meglumine antimoniate seven with primary and five with recurrent lesions. The majority (11/12) met all cure criteria after 1-7 sessions of meglumine antimoniate administration (1-5 mL). Adverse effects comprised mainly of local pain and edema. Intralesional meglumine antimoniate administration could be an excellent alternative treatment for uncomplicated CL; however, controlled clinical trials are needed to test the efficacy and safety thereof.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Leishmaniasis Cutánea
/
Antimoniato de Meglumina
/
Antiprotozoarios
Límite:
Adulto
/
Femenino
/
Humanos
/
Lactante
/
Masculino
Idioma:
Inglés
Revista:
Rev. Soc. Bras. Med. Trop
Asunto de la revista:
Medicina Tropical
Año:
2019
Tipo del documento:
Artículo
País de afiliación:
Colombia
Institución/País de afiliación:
Universidad CES/CO
/
Universidad de Antioquia/CO
Similares
MEDLINE
...
LILACS
LIS